Radiation oncology company Accuray has been granted US Food and Drug Administration (FDA) approval for the Dose Control System, a new feature for the company’s TomoTherapy system.

The TomoTherapy system enables doses to be precisely applied to target structures while sparing healthy tissue.

The Dose Control System ensures a stable output for treatments with a long duration, including total marrow and total body irradiation.

Accuray president and CEO Euan Thomson said that the Dose Control System can improve the TomoTherapy system’s performance.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now